{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:01:35Z","timestamp":1777305695710,"version":"3.51.4"},"reference-count":117,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T00:00:00Z","timestamp":1546732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mature B cell lymphomas account for approximately 60% of all cases of non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) in children and adolescents and includes Burkitt lymphoma (<jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>), diffuse large B cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>) and other less common histologies. The outcome for patients treated with modern regimens in resource\u2010intensive settings is excellent. Improvements in care have been accomplished through enhanced supportive therapy, including tumour lysis management and incremental refinement of chemotherapy backbones via cooperative group clinical trials in which patients receive risk group\u2010specific intensive chemotherapy. More recent trials have established the safety and efficacy of immunotherapy. Ongoing work is required to address the substantial burden of acute therapy\u2010related toxicity, as well as the identification of effective therapies for those patients with relapsed and refractory disease, for whom outcomes remain very poor. In this review we will summarize the results from recent therapeutic clinical trials, describe the evidence to support the inclusion of rituximab and review the rationale for the investigation of several new categories of novel agents for mature B cell lymphomas in children and adolescents.<\/jats:p>","DOI":"10.1111\/bjh.15734","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T05:52:42Z","timestamp":1546840362000},"page":"1071-1085","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Mature B\u2010<scp>NHL<\/scp> in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-8403","authenticated-orcid":false,"given":"Grace","family":"Egan","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology The Hospital for Sick Children Department of Pediatrics University of Toronto Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Medical City Children's Hospital and Texas Oncology Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology The Hospital for Sick Children Department of Pediatrics University of Toronto Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,1,6]]},"reference":[{"key":"e_1_2_22_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1161"},{"key":"e_1_2_22_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"key":"e_1_2_22_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_22_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"e_1_2_22_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_22_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.677534"},{"key":"e_1_2_22_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339"},{"key":"e_1_2_22_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183"},{"key":"e_1_2_22_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1785-2"},{"issue":"1","key":"e_1_2_22_12_1","first-page":"71","article-title":"Clinical characteristics and outcome of pediatric and adolescent patients with primary central nervous system lymphoma (PCNSL) \u2010 the EICNHL\/i\u2010BFM\/COG\/IPCG study groups\u2019 experience","volume":"182","author":"Attarbaschi A.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13764"},{"key":"e_1_2_22_14_1","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V126.23.2726.2726","article-title":"Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R\u2010CHP) for patients with previously untreated diffuse large B\u2010cell lymphoma (DLBCL): preliminary results of a phase Ib dose\u2010escalation","volume":"126","author":"Bartlett N.L.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_22_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1256481"},{"key":"e_1_2_22_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"e_1_2_22_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25072"},{"key":"e_1_2_22_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.10512"},{"key":"e_1_2_22_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15532"},{"issue":"1","key":"e_1_2_22_20_1","first-page":"4124","article-title":"Results of inter\u2010B\u2010NHL ritux 2010 \u2010 phase II study of DA\u2010EPOCH\u2010R for children and adolescents with primary mediastinal large B\u2010cell lymphoma (PMLBL) on behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG)","volume":"130","author":"Burke G.A.A.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_22_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1967)20:5<756::AID-CNCR2820200530>3.0.CO;2-P"},{"key":"e_1_2_22_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_22_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_2_22_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245"},{"key":"e_1_2_22_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217"},{"key":"e_1_2_22_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_22_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30426-1"},{"key":"e_1_2_22_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14820"},{"key":"e_1_2_22_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_22_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"e_1_2_22_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"e_1_2_22_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7211"},{"key":"e_1_2_22_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29502"},{"key":"e_1_2_22_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4901"},{"key":"e_1_2_22_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_22_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_22_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422709"},{"key":"e_1_2_22_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-791566"},{"key":"e_1_2_22_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437624"},{"key":"e_1_2_22_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24722"},{"key":"e_1_2_22_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.386"},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14951"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"e_1_2_22_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13040"},{"issue":"1","key":"e_1_2_22_48_1","first-page":"11","article-title":"Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20\u00a0+\u00a0 mature B\u2010cell lymphoma","volume":"182","author":"Goldman S.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_22_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_22_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021"},{"key":"e_1_2_22_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3545"},{"key":"e_1_2_22_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_2_22_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_22_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"e_1_2_22_55_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.121434"},{"key":"e_1_2_22_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_22_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_22_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_22_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136465"},{"key":"e_1_2_22_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388470"},{"key":"e_1_2_22_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2784"},{"key":"e_1_2_22_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30153-4"},{"key":"e_1_2_22_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3003"},{"key":"e_1_2_22_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_22_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22047"},{"key":"e_1_2_22_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_22_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"issue":"15","key":"e_1_2_22_68_1","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized Intergroup trial Inter\u2010B\u2010NHL Ritux 2010 for children and adolescents with high\u2010risk B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) and mature acute leukemia (B\u2010AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen","volume":"34","author":"Minard\u2010Colin V.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_22_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_2_22_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13765"},{"key":"e_1_2_22_71_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_22_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_22_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197710)40:4<1410::AID-CNCR2820400408>3.0.CO;2-M"},{"key":"e_1_2_22_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910170404"},{"key":"e_1_2_22_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910260302"},{"key":"e_1_2_22_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030809"},{"key":"e_1_2_22_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_22_78_1","first-page":"35","volume-title":"Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975\u20131995","author":"Percy C.L.","year":"1999"},{"key":"e_1_2_22_79_1","first-page":"314","article-title":"B\u2010cell non\u2010Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report","volume":"1","author":"Perkins S.L.","year":"2003","journal-title":"Clinical Advances in Hematology & Oncology: H&O"},{"key":"e_1_2_22_80_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305656110"},{"key":"e_1_2_22_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_22_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.622.622"},{"key":"e_1_2_22_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_2_22_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06988.x"},{"key":"e_1_2_22_85_1","first-page":"3294","article-title":"Improved treatment results in childhood B\u2010cell neoplasms with tailored intensification of therapy: a report of the Berlin\u2010Frankfurt\u2010Munster Group Trial NHL\u2010BFM 90","volume":"94","author":"Reiter A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_22_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01317-3"},{"key":"e_1_2_22_87_1","first-page":"5","article-title":"Early response data for pediatric patients with non\u2010Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T\u2010cells","volume":"182","author":"Rivers J.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_22_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.156885"},{"key":"e_1_2_22_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26932"},{"key":"e_1_2_22_90_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"e_1_2_22_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7203"},{"key":"e_1_2_22_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.194"},{"key":"e_1_2_22_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802561"},{"key":"e_1_2_22_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"e_1_2_22_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.378"},{"issue":"1","key":"e_1_2_22_96_1","first-page":"577","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B\u2010cell lymphoma","volume":"130","author":"Schuster S.J.","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_22_97_1","first-page":"2821","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant\u2010ineligible patients with relapsed\/refractory (R\/R) diffuse large B\u2010cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study","volume":"130","author":"Sehn L.H.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_22_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.151"},{"key":"e_1_2_22_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_22_100_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_22_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_22_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14812"},{"key":"e_1_2_22_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6984"},{"issue":"1","key":"e_1_2_22_104_1","first-page":"1540","article-title":"Polatuzumab vedotin alone or in combination with obinutuzumab synergistically enhances in\u2010vitro cytotoxicity and cytokine release against CD20\u00a0+\u00a0\/ CD79b+ Burkitt lymphoma (BL)\/primary mediastinal large B cell lymphoma (PMBL)","volume":"130","author":"Tiwari A.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_22_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"e_1_2_22_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_2_22_107_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"e_1_2_22_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_22_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_22_110_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx764"},{"key":"e_1_2_22_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"e_1_2_22_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1305983"},{"key":"e_1_2_22_113_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169656"},{"key":"e_1_2_22_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3937"},{"key":"e_1_2_22_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.2"},{"key":"e_1_2_22_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_49"},{"key":"e_1_2_22_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"},{"key":"e_1_2_22_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764258"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15734","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:25:39Z","timestamp":1694381139000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,6]]},"references-count":117,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bjh.15734"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15734","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,6]]},"assertion":[{"value":"2019-01-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}